Where does DBV Technologies rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), DBV Technologies ranks #15,945 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does DBV Technologies hold?

DBV Technologies holds 18 US utility patents granted between 2015 and 2025, spanning 7 technology areas.

What is DBV Technologies's Innovation Score?

DBV Technologies has an Innovation Score of 34.1 out of 100 (47th percentile of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does DBV Technologies focus on?

DBV Technologies's top technology area is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations) with 12 patents, ranking #1,593 of 6,058 assignees active in that subclass. Grants appear in 7 CPC subclasses total.

Is DBV Technologies's patent grant rate increasing or decreasing?

DBV Technologies's recent grant velocity is +50% compared to the prior five-year period (grant years, not application filing dates). This indicates accelerating grant output.

What does claim depth mean for DBV Technologies's patents?

DBV Technologies's patents average 10.9 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the DBV Technologies patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView Foreign Corporation

DBV Technologies

USPTO PatentsView assignee record - 18 granted patents across 7 technology areas, recorded in grant years 2015–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, DBV ranks #15,945 of 49,997 tracked US assignees by granted-patent volume, with 18 patents across 7 technology areas.

#15,945
of 49,997 US assignees by volume: 47th percentile
by Innovation Score (34.1/100): 10.9
avg claims per patent: +50%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R15945 · Foreign Corporation #15,945 · 18 grants

GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-PAR · TYPE-FRNCORP · VEL-SURGE · BOOK-FULL

GRANTS-MICRO 18 grants
MID-PACK #15,945/49,997
PHOTO-FINISH CytoChip
CPC-NARROW A61P · 7 areas
INNOV-THIN 34.1/100
CLAIMS-PAR 10.9 claims/avg
TYPE-FRNCORP Foreign Corp
VEL-SURGE +50% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: CytoChip Inc. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How DBV’s 34.1 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 10.2 pts (30%) Velocity 8.0 pts (23%) Breadth 9.4 pts (27%) Claim depth 6.6 pts (19%)

Qualcomm Incorporated · highest

85
DBV · this assignee

34
3D Lighting… · lowest

7

What this shows DBV's Innovation Score is 34.1/100 (47th percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for DBV?

Each dot is one of DBV’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). DBV’s own 10.9 claims/patent is ABOVE the 7.7 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.

DBV vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where DBV's grants concentrate

DBV Technologies is a focused PatentsView assignee: 7 CPC subclasses with 66.7% of grants classified under A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations). Peak complete grant year is 2024 (4 grants) versus a trough of 1 in 2017. By volume, DBV sits between CytoChip Inc. and Dentlytec G.P.L. Ltd..

DBV's three-year grant acceleration

DBV Technologies shows 6 grants in 2022–2024 against only 5 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Cytochip

18
Daher Aerospace

18
Daido Kogyo

18
Dakang Holding

18
DDK

18
Deepmotor

18
Densbits

18
Dentlytec G P L

18
DBV ◀

18

What this shows DBV holds 18 patents at rank #15,943, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near DBV

By rank, the assignees closest to #15,943 in granted patent volume.

Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)

Other assignees with the most granted patents in DBV's primary technology class.

DBV's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

34 47th percentile higher than 47% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2015–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table

DBV Technologies patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2015	2	11.1%
2017	1	5.6%
2018	1	5.6%
2019	2	11.1%
2020	1	5.6%
2021	2	11.1%
2023	2	11.1%
2024	4	22.2%
2025partial year	3	16.7%

Which technologies does DBV Technologies patent most?

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 12

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 12

G01N - Investigating OR Analysing Materials BY Determining Their Chemical OR Physical Properties 2

C07K - Peptides 1

A61B - DIAGNOSIS; SURGERY; Identification 1

A61M - Devices FOR Introducing Media Into, OR Onto, THE Body ; Devices FOR Transducing Body Media OR FOR Taking Media From THE Body ; Devices FOR Producing OR Ending Sleep OR Stupor 1

Y10S - Technical Subjects Covered BY Former Uspc Cross-reference ART Collections [XRACs] AND Digests 1

Top 7 of 7 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

DBV Technologies's patent record in context - here's where to go next.

DBV Technologies's lead technology class is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations), 66.7% of its portfolio - see every assignee active in that class. Explore A61P
Ranked #15,945 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare DBV Technologies against CytoChip Inc., an assignee filing at a similar volume. Compare portfolios
Innovation Score of 34.1/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.